News
MREO
2.780
-0.36%
-0.010
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 1d ago
Weekly Report: what happened at MREO last week (0415-0419)?
Weekly Report · 1d ago
BRIEF-Rubric Capital Enters Into Letter Agreement With Mereo Biopharma Group Regarding Cooperation Deal
Rubric Capital Enters Into Letter Agreement With Mereo Biopharma Group Regarding Cooperation Deal. Company says it has entered into a letter agreement with Mereo for a cooperation deal. Mereo is a manufacturer of biopharmaceuticals for the treatment of cancer and other diseases.
Reuters · 04/16 21:58
Weekly Report: what happened at MREO last week (0408-0412)?
Weekly Report · 04/15 10:21
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NASDAQ · 04/12 13:35
Mereo Biopharma Group Plc: A Buy Rating Backed by Strong Leadership and Promising Drug Pipeline
TipRanks · 04/10 10:26
Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham
Dow Jones · 04/10 10:21
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Benzinga · 04/10 10:11
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
Seeking Alpha · 04/10 08:08
Weekly Report: what happened at MREO last week (0401-0405)?
Weekly Report · 04/08 10:24
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Dr. Denise Scots-Knight will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024. Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on rare diseases.
Barchart · 04/03 06:30
Weekly Report: what happened at MREO last week (0325-0329)?
Weekly Report · 04/01 10:23
Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Dow Jones · 03/28 14:32
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Benzinga · 03/28 14:22
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)
TipRanks · 03/28 10:30
Mereo BioPharma Group Is Maintained at Buy by Needham
Dow Jones · 03/28 10:12
Mereo BioPharma Group Price Target Raised to $6.00/Share From $5.00 by Needham
Dow Jones · 03/28 10:12
Needham Maintains Buy on Mereo BioPharma Group, Raises Price Target to $6
Benzinga · 03/28 10:05
Mereo BioPharma Group GAAP EPS of -$0.04
As of December 31, 2023, the Company had cash and cash equivalents of $57.4 million. Mereo BioPharma Group plc expects to fund clinical trials and other activities into 2026. The company posted a FY GAAP EPS of -$0.04.
Seeking Alpha · 03/27 20:49
Mereo BioPharma Group FY EPS $(0.04) Up From $(0.07) YoY, Sales $10.00M
Benzinga · 03/27 20:21
More
Webull provides a variety of real-time MREO stock news. You can receive the latest news about Mereo Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).